LON:CRTX CRISM Therapeutics (CRTX) Share Price, News & Analysis GBX 9.50 -0.75 (-7.32%) As of 08:19 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsBuy This Stock About CRISM Therapeutics Stock (LON:CRTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CRISM Therapeutics alerts:Sign Up Key Stats Today's Range 9.50▼ 1150-Day Range 10▼ 13.6552-Week Range 8▼ 23Volume30,623 shsAverage Volume290,154 shsMarket Capitalization£5.15 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview CRISM Therapeutics Corporation is clinical stage company, having developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs. ChemoSeed, CRISM’s lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective. CRISM will initiate its registration-grade Phase 2 clinical trial of irinotecan-ChemoSeed in patients with surgically resectable glioblastoma in Q1 2026. For more information please visit: https://www.crismtherapeutics.com Read More Receive CRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CRISM Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CRTX Stock News HeadlinesCRISM Therapeutics Upsizes Oversubscribed Retail Offer to Fund Cancer Drug Delivery TrialsMay 28, 2026 | tipranks.comCRISM Therapeutics Raises Funds for Glioblastoma TrialDecember 15, 2025 | tipranks.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.June 24 at 1:00 AM | Profits Run (Ad)CRISM Therapeutics Launches £100,000 Retail Offer to Fund Clinical TrialDecember 10, 2025 | tipranks.comCRISM Therapeutics Secures £1 Million for Phase 2 Glioblastoma TrialDecember 10, 2025 | tipranks.comCRISM Therapeutics Secures Approval for Phase 2 Glioblastoma TrialSeptember 1, 2025 | tipranks.comCRISM Therapeutics Raises £874,021 to Advance Cancer Treatment TechnologyJuly 3, 2025 | tipranks.comCRISM Director Increases Stake in CompanyApril 7, 2025 | tipranks.comSee More Headlines CRTX Stock Analysis - Frequently Asked Questions How have CRTX shares performed this year? CRISM Therapeutics' stock was trading at GBX 9 on January 1st, 2026. Since then, CRTX stock has increased by 5.6% and is now trading at GBX 9.50. How were CRISM Therapeutics' earnings last quarter? CRISM Therapeutics Corporation (LON:CRTX) announced its earnings results on Monday, September, 15th. The company reported ($2.80) earnings per share for the quarter. How do I buy shares of CRISM Therapeutics? Shares of CRTX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. Company Calendar Last Earnings9/15/2025Today6/24/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorBasic Materials Industry Other Industrial Metals & Mining Sub-IndustryN/A Current SymbolLON:CRTX CIKN/A Webwww.crismtherapeutics.com PhoneN/AFaxN/AEmployees4Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (4.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£792.20 thousand Net MarginsN/A Pretax MarginN/A Return on Equity-109.55% Return on Assets-26.77% Debt Debt-to-Equity RatioN/A Current Ratio3.65 Quick RatioN/A Sales & Book Value Annual Sales£25 thousand Price / Sales206.09 Cash FlowN/A Price / Cash FlowN/A Book ValueGBX 43.03 per share Price / Book0.22Miscellaneous Outstanding Shares54,235,000Free FloatN/AMarket Cap£5.15 million OptionableN/A Beta0.59 The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (LON:CRTX) was last updated on 6/24/2026 by MarketBeat.com Staff. From Our PartnersThe 0DTE trade most investors get wrongZero-days-to-expiration trades happen every single day - and most traders either ignore them or use them wrong...Base Camp Trading | SponsoredFirm That Predicted 2008, 2020, 2022: Right Now Looks WorseThe firm that predicted the dot-com crash, the 2008 financial crisis, the 2020 COVID crash, and the 2022 bear ...TradeSmith | SponsoredThe Treasury just bought its own debtOn April 16th, the U.S. Treasury executed a $15 billion buyback of its own debt - the largest in history - whi...Golden Portfolio | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely, LLC | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredMy feud with Zohran MamdaniNearly 40% of Americans now hold a positive view of socialism - and former hedge fund manager Whitney Tilson s...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CRISM Therapeutics Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share CRISM Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
